
Multiyear Follow-up Study Shows Positive Results for Hemophilia B Gene Therapy
Results of a follow-up study of people with hemophilia B who had been treated with Beqvez (fidanacogene elaparvovec), a gene therapy, showed sustained factor IX activity over three to six years, and during that period, only low-grade adverse effects. The …